Answers are grounded in this paper and cite their sources.
In this fourth episode of “Type 2 Diabetes — Controlling the Epidemic,” a four-part Double Take video miniseries from the New England Journal of Medicine, Drs. Jane E.B. Reusch (University of Colorado) and E. Dale Abel (UCLA) describe old and new drugs available for diabetes therapy and discuss their benefits and side effects. Dr. Monica Peek (University of Chicago) and other experts reflect on the cost barriers faced by patients with diabetes and strategies used to overcome those challenges. For further reading, the following articles, referenced in this video, are available at NEJM.org, where you can also watch Quick Take video summaries of the research articles: Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin (Rosenstock et al., in the July 27, 2023, issue), Building a Better Insulin — Whom Will It Help? (Reusch, in the July 27, 2023, issue), Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding et al., in the March 18, 2021, issue), Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff et al., in the July 21, 2022, issue), and Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes (Gerstein et al., in the September 2, 2021, issue).
No takes yet. Share an insight, caveat, or question.
Abel et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: